Recognized for Contributions to the Development of Combination Drugs for Hypertension

"Will Continue Patient-Centered R&D Innovation"

Lim Ho Taek, Head of the Pharmaceutical Innovation Center at Hanmi Pharmaceutical, has been honored with the 'Korea Engineer Award'.


Hanmi Pharmaceutical announced on July 2 that Lim was recognized at the Korea Engineer Awards ceremony held on the 23rd of last month at the Westin Chosun Hotel in Seoul, for his research achievements in leading the development of major combination and improved drugs such as Amotartan and Esomezol.


On the 23rd of last month, at the ceremony of the 'Korea Engineer Awards' held at the Westin Chosun Hotel in Seoul, Koo Hyukjae, First Vice Minister of the Ministry of Science and ICT (first from the left), and Lim Hotaek, Head of the Pharmaceutical Innovation Center at Hanmi Pharm (third from the left), are taking a commemorative photo. Hanmi Pharm

On the 23rd of last month, at the ceremony of the 'Korea Engineer Awards' held at the Westin Chosun Hotel in Seoul, Koo Hyukjae, First Vice Minister of the Ministry of Science and ICT (first from the left), and Lim Hotaek, Head of the Pharmaceutical Innovation Center at Hanmi Pharm (third from the left), are taking a commemorative photo. Hanmi Pharm

View original image

The Korea Engineer Award is a program hosted by the Ministry of Science and ICT and organized by the Korea Industrial Technology Association. It is a prestigious domestic award that recognizes outstanding engineers who have contributed to technological innovation in the industrial field.


For over 20 years, Lim has dedicated himself to research and development (R&D) in the pharmaceutical sector, earning recognition for enhancing patient convenience and safety through the development of combination and improved drugs. In particular, he participated in developing combination drugs that treat both hypertension and dyslipidemia, helping Hanmi Pharmaceutical's product lineup secure a strong competitive position in the domestic hypertension treatment market.



Lim stated, "The essence of formulation research is to improve the treatment experience for patients by developing technologies that reduce the burden of medication while increasing treatment persistence and efficacy. I will continue to drive patient-centered R&D innovation, contributing to public health and enhancing global competitiveness."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing